A Night of Excellence: Edgar B. Herwick III to Illuminate the 58th Annual Bell Ringer Awards

Karen Reynolds — Thu, 12 Mar 2026 00:39:36 GMT

The Stage is Set for Brilliance

In the heart of Boston, an evening of recognition and celebration is on the horizon. The PR Club of New England has officially announced that the 58th Annual Bell Ringer Awards will be presented by Edgar B. Herwick III, the esteemed GBH News host. This announcement sets the stage for an event that has been a cornerstone in the PR and communications industry for nearly six decades. Scheduled for June 4, 2026, at the Museum of Science, this ceremony is not just an event; it's a grand celebration of excellence in the field.

Spotlight on Achievement

The Bell Ringer Awards are more than just trophies and accolades; they are a testament to the innovative spirit and tireless dedication of professionals in the PR and communications world. From groundbreaking campaigns to exemplary events, the awards shine a light on those who have set new benchmarks of success. And this year, the spotlight also falls on students, recognizing the next generation of industry leaders. Adding to the excitement, GBH will be the beneficiary of all proceeds from the annual Bell Ringers 50/50 Raffle, a gesture that underscores the community's commitment to supporting media excellence.

The call for nominations has been sounded, inviting industry professionals to submit their entries by April 21, 2026. The anticipation builds as the deadline approaches, with the winners set to be unveiled at the ceremony. This is a clarion call to those who have dared to dream big and push boundaries in their communications endeavors.

About the PR Club

Since its inception in 1948, the PR Club (formerly known as the Publicity Club of New England) has been at the forefront of fostering growth and excellence in the communications industry. With a focus on public relations, promotions, and marketing, the club offers a plethora of opportunities for professional development and networking. Through monthly programs, social events, and the much-anticipated Bell Ringer Awards Ceremony, the PR Club champions the cause of communications professionals across New England. For more information about the club and how to get involved, visit www.PRClub.org.

As the event draws nearer, the communications industry watches with bated breath, ready to celebrate the achievements of its brightest stars. The 58th Annual Bell Ringer Awards, with Edgar B. Herwick III at the helm, promises to be an evening of inspiration and aspiration, reminding everyone of the power of effective communication and the endless possibilities it holds.

OS Therapies Inc.: Pioneering the Future of Osteosarcoma Treatment

Karen Reynolds — Tue, 11 Nov 2025 16:27:49 GMT

A Breakthrough in Osteosarcoma Treatment

In a significant development for patients suffering from recurrent, fully resected, pulmonary metastatic osteosarcoma, OS Therapies Inc. (OSTX) has made substantial progress in its clinical, regulatory, and financial endeavors. The spotlight shines on OST-HER2, the company's flagship therapy, which has recently been recognized by the FDA as meeting the biological definition of a Regenerative Medicine Advanced Therapy (RMAT). This designation is a precursor to an Accelerated Approval submission, marking a pivotal step forward in the therapy's journey towards reaching patients in dire need.

The promising results from the Phase 2b trial of OST-HER2, showcasing a statistically significant improvement in 12-month Event Free Survival (EFS) rates, alongside encouraging interim 2-year Overall Survival (OS) data, underscore the therapy's potential clinical benefit. These findings are not just numbers—they represent hope for a community that has been waiting over 40 years for a breakthrough in osteosarcoma treatment.

Expanding Horizons and Strengthening Financials

OS Therapies isn't resting on its laurels with OST-HER2. The acquisition of Ayala’s listeria immunotherapy platform has enriched its portfolio, adding four clinical-stage and eight pre-clinical-stage programs to its arsenal. Furthermore, the establishment of OS Animal Health to explore OST-HER2's application in treating canine osteosarcoma highlights the company’s innovative approach and commitment to broadening the impact of its research.

On the financial front, OS Therapies has demonstrated strategic acumen, reporting a net loss of $4.5M in 2Q25 amidst increased R&D and G&A expenses. However, this loss is a testament to the company's investment in its future, with cash reserves bolstered through recent financing efforts, ensuring a runway extending into 2027. These maneuvers, coupled with the potential monetization of a Priority Review Voucher (PRV) anticipated to be worth around $155–160M, position OS Therapies on solid footing as it gears up for a U.S. launch in the first half of 2026.

Stonegate Capital Partners Lends Its Support

Stonegate Capital Partners has initiated coverage on OS Therapies, offering a vote of confidence in the company’s trajectory. Utilizing a probability-adjusted Discounted Cash Flow Model, Stonegate projects a valuation range for OSTX between $7.09 and $9.94, a figure that reflects both the inherent risks and the substantial rewards associated with the long-term nature of the biopharmaceutical industry. Such endorsements underline the market's recognition of OS Therapies' potential to redefine the treatment landscape for osteosarcoma.

As OS Therapies Inc. strides towards a historic commercial launch, supported by a solid partnership with Eversana for U.S. commercialization, the medical community and patients alike watch with bated breath. The journey of OST-HER2 from promising research to a potential lifesaver is a beacon of hope, not just for those battling osteosarcoma, but for anyone who believes in the power of innovation to conquer the unconquerable. With a clear path laid out by regulatory bodies, a fortified financial position, and the backing of Stonegate Capital Partners, OS Therapies is poised to make a monumental impact.

Karen Reynolds's Articles